The research and development move of the K-mRNA Consortium formed to develop the next-generation COVID-19 vaccine is expected to gain further momentum.

The consortium consisting of Hanmi, ST Pharm, GC Pharma and KIMCo announced on the 9th that Dong-A ST, a major pharmaceutical company in the development and production of specialized drugs in Korea, and E-Cell, a company specializing in bio-original materials, participated in the consortium. Since the launch of the consortium in June, the progress of the project has accelerated, and material companies and others seem to be joining as partners. Dong-A ST is one of the representative pharmaceutical R&D companies in the domestic pharmaceutical bio industry, an